Company / Capital Returned to Shareholders
Haemonetics Capital Returned to Shareholders History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$225.0M
FY2024
5-year range
$0 / $225.0M
FY2020-FY2024
Trend
-
vs FY2023
Sector context
#50 of 103
Health Care
What the data says
At $225M, Haemonetics's capital returned to shareholders ranks #50 of 103 in the Health Care sector. Capital Returned to Shareholders has fluctuated over the past 9 years, ranging from $0 in FY2023 to $225M in FY2024.
Based on SEC 10-K filings.
$225M in FY2024 with a 5-year CAGR of +5.2%.
Improved from $75M to $225M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +5.2%
- 10-Year CAGR
- -
Sector benchmark
#50 of 103 in Health CareTop 49% of 103This company $225.0M Sector average $721.8M
▼
-68.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.2%, indicating consistent growth.
- Ranks #50 out of 103 companies in the Health Care sector.
- Lowest capital returned to shareholders in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.44 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $225.0M | - |
| FY2023 | $0 | -100.0% |
| FY2022 | $75.0M | - |
| FY2021 | $0 | - |
| FY2020 | $0 | -100.0% |
| FY2019 | $175.0M | +9.4% |
| FY2018 | $160.0M | +60.0% |
| FY2017 | $100.0M | - |
| FY2016 | $0 | -100.0% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026